Adcoris is a clinical-stage innovative biopharmaceutical company. We possess proprietary next-generation ADC and AXC conjugation technology platforms with independent intellectual property rights, as well as a range of antibody-conjugate drugs, including single-agent antibody, dual-agent antibody, and dual-agent bispecific ADCs. Leveraging these unique technology platforms, we are independently developing multiple products at various stages of research and development. Adcoris is dedicated to advancing next-generation ADC drugs to address unmet medical needs in oncology and autoimmune diseases.
We welcome collaboration with external partners in various areas such as technology platforms, new product co-development, and product licensing. We believe that by leveraging each other's expertise and resources, we can accelerate the commercialization of next-generation ADC products. If you are interested in exploring collaboration opportunities or learning more, please feel free to contact us. We look forward to working with you to drive innovation in the field of oncology.
Welcome global partners to contact us at BD@adcoris.com.cn.
We actively seek innovative collaborations and strategic business development opportunities.
If you are interested in collaborating with us, please feel free to contact us at BD@adcoris.com.cn.